Facebook
X
LinkedIn
ForwardRadiobiological and Translational Aspects of RPTs
This session explores some of the basic radiobiologic principles of radiopharmaceutical therapy. Topics that may be addressed include, but are not limited to, relative biological effectiveness (RBE), ranges, linear energy transfer (LET), radionuclide activity, pharmacokinetics, and pharmacodynamics. It also explores innovative preclinical and translational research with radiopharmaceuticals, including combination therapies to engage an anti-tumor immune response.
Target Audience
This meeting was designed to meet the interests of medical oncologists, radiation oncologists, physicists, nurses, diagnostic radiologists, radiation therapists, radiation dosimetrists, specialists, nuclear physicians and practice administrators.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Understand basic radiobiological principles of various forms of radiopharmaceuticals.
- Describe novel strategies of pre-clinical to clinical translation in the field of radiopharmaceuticals.
- Describe some of the scientific rationale behind novel pairings of radiopharmaceuticals with other systemic agents.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 0.75 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 Certificate of AttendanceThis activity was designated for 0.75 AMA PRA Category 1 Credit™.